Abnormal Motor Cortex Excitability in Preclinical and Very Early Huntington's Disease

Biological Psychiatry

Volumn 65, Issue 11, 2009, Pages 959-965

  Schippling, Sven ^a,b   Schneider, Susanne A ^a   Bhatia, Khailash P ^a   Münchau, Alexander ^b   Rothwell, John C ^a   Tabrizi, Sarah J ^a   Orth, Michael ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cortico spinal system; Huntington's disease; short latency afferent inhibition; transcranial magnetic stimulation; UHDRS

Indexed keywords

ADULT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROMYOGRAPHY; FEMALE; GENETIC DISORDER; HUMAN; HUNTINGTON CHOREA; MALE; MEDIAN NERVE; MOTOR CORTEX; NERVE CELL EXCITABILITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RATING SCALE; SOMATOSENSORY STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; UNIFIED HUNTINGTON DISEASE RATING SCALE;

ADULT; ANALYSIS OF VARIANCE; BRAIN MAPPING; ELECTRIC STIMULATION; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MEDIAN NERVE; MIDDLE AGED; MOTOR CORTEX; NEURAL CONDUCTION; REACTION TIME; SPREADING CORTICAL DEPRESSION; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 67349209867     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.12.026     Document Type: Article

References (43)

1. Walker F.O. Huntington's disease. Lancet 369 (2007) 218-228
2. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 21 (2006) 1317-1325
3. Henley S.M., Frost C., MacManus D.G., Warner T.T., Fox N.C., and Tabrizi S.J. Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 67 (2006) 694-696
4. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15 (2006) 965-977
5. Strand A.D., Baquet Z.C., Aragaki A.K., Holmans P., Yang L., Cleren C., et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 27 (2007) 11758-11768
6. Eisen A., Bohlega S., Bloch M., and Hayden M. Silent periods, long-latency reflexes and cortical MEPs in Huntington's disease and at-risk relatives. Electroencephalogr Clin Neurophysiol 74 (1989) 444-449
7. Hanajima R., Ugawa Y., Terao Y., Furubayashi T., Machii K., Shiio Y., et al. Intracortical inhibition of the motor cortex is normal in chorea. J Neurol Neurosurg Psychiatry 66 (1999) 783-786
8. Abbruzzese G., Buccolieri A., Marchese R., Trompetto C., Mandich P., and Schieppati M. Intracortical inhibition and facilitation are abnormal in Huntington's disease: A paired magnetic stimulation study. Neurosci Lett 228 (1997) 87-90
9. Priori A., Polidori L., Rona S., Manfredi M., and Berardelli A. Spinal and cortical inhibition in Huntington's chorea. Mov Disord 15 (2000) 938-946
10. Modugno N., Curra A., Giovannelli M., Priori A., Squitieri F., Ruggieri S., et al. The prolonged cortical silent period in patients with Huntington's disease. Clin Neurophysiol 112 (2001) 1470-1474
11. Nardone R., Lochner P., Marth R., Ausserer H., Bratti A., and Tezzon F. Abnormal intracortical facilitation in early-stage Huntington's disease. Clin Neurophysiol 118 (2007) 1149-1154
12. Lefaucheur J.P., Bachoud-Levi A.C., Bourdet C., Grandmougin T., Hantraye P., Cesaro P., et al. Clinical relevance of electrophysiological tests in the assessment of patients with Huntington's disease. Mov Disord 17 (2002) 1294-1301
13. Tegenthoff M., Vorgerd M., Juskowiak F., Roos V., and Malin J.P. Postexcitatory inhibition after transcranial magnetic single and double brain stimulation in Huntington's disease. Electroencephalogr Clin Neurophysiol 101 (1996) 298-303
14. Lefaucheur J.P., Ménard-Lefaucheur I., Maison P., Baudic S., Cesaro P., Peschanski M., and Bachoud-Lévi A.C. Electrophysiological deterioration over time in patients with Huntington's disease. Mov Disord 21 (2006) 1350-1354
15. Butefisch C.M., Netz J., Wessling M., Seitz R.J., and Homberg V. Remote changes in cortical excitability after stroke. Brain 126 (2003) 470-481
16. Orth M., Snijders A.H., and Rothwell J.C. The variability of intracortical inhibition and facilitation. Clin Neurophysiol 114 (2003) 2362-2369
17. Ilic T.V., Meintzschel F., Cleff U., Ruge D., Kessler K.R., and Ziemann U. Short-interval paired-pulse inhibition and facilitation of human motor cortex: the dimension of stimulus intensity. J Physiol 545 (2002) 153-167
18. Orth M., and Rothwell J.C. The cortical silent period: intrinsic variability and relation to the waveform of the transcranial magnetic stimulation pulse. Clin Neurophysiol 115 (2004) 1076-1082
19. Abbruzzese G., Dall'Agata D., Morena M., Reni L., and Favale E. Abnormalities of parietal and prerolandic somatosensory evoked potentials in Huntington's disease. Electroencephalogr Clin Neurophysiol 77 (1990) 340-346
20. Tokimura H., Di Lazzaro V., Tokimura Y., Oliviero A., Profice P., Insola A., et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol 523 (2000) 503-513
21. Huntington Study Group. Unified Huntington's Disease Rating Scale: Reliability and consistency. Mov Disord 11 (1996) 136-142
22. Shoulson I., and Fahn S. Huntington disease: Clinical care and evaluation. Neurology 29 (1979) 1-3
23. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., and Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65 (2004) 267-277
24. Orth M., Amann B., Ratnaraj N., Patsalos P.N., and Rothwell J.C. Caffeine has no effect on measures of cortical excitability. Clin Neurophysiol 116 (2005) 308-314
25. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., et al. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci 19 (1999) 2522-2534
26. Gomez-Tortosa E., MacDonald M.E., Friend J.C., Taylor S.A., Weiler L.J., Cupples L.A., et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 49 (2001) 29-34
27. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology 60 (2003) 1615-1620
28. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., and Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11 (1995) 155-163
29. Nasir J., Floresco S.B., O'Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81 (1995) 811-823
30. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269 (1995) 407-410
31. Paulsen J.S., Magnotta V.A., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 59 (2006) 57-63
32. Nopoulos P., Magnotta V.A., Mikos A., Paulson H., Andreasen N.C., and Paulsen J.S. Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry 164 (2007) 1428-1434
33. Di Lazzaro V., Oliviero A., Profice P., Pennisi M.A., Di Giovanni S., Zito G., et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res 135 (2000) 455-461
34. Restuccia D., Della Marca G., Valeriani M., Rubino M., Paciello N., Vollono C., et al. Influence of cholinergic circuitries in generation of high-frequency somatosensory evoked potentials. Clin Neurophysiol 114 (2003) 1538-1548
35. Suzuki M., Desmond T.J., Albin R.L., and Frey K.A. Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers. Synapse 41 (2001) 329-336
36. Vetter J.M., Jehle T., Heinemeyer J., Franz P., Behrens P.F., Jackisch R., et al. Mice transgenic for exon 1 of Huntington's disease: Properties of cholinergic and dopaminergic pre-synaptic function in the striatum. J Neurochem 85 (2003) 1054-1063
37. Vonsattel J.P., and DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 57 (1998) 369-384
38. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., and Richardson Jr. E.P. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44 (1985) 559-577
39. Smith R., Chung H., Rundquist S., Maat-Schieman M.L., Colgan L., Englund E., et al. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet 15 (2006) 3119-3131
40. Gomez-Anson B., Alegret M., Munoz E., Sainz A., Monte G.C., and Tolosa E. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology 68 (2007) 906-910
41. Di Lazzaro V., Oliviero A., Tonali P.A., Marra C., Daniele A., Profice P., et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 59 (2002) 392-397
42. Ferrante R.J., Beal M.F., Kowall N.W., Richardson Jr. E.P., and Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 411 (1987) 162-166
43. Clark A.W., Parhad I.M., Folstein S.E., Whitehouse P.J., Hedreen J.C., Price D.L., et al. The nucleus basalis in Huntington's disease. Neurology 33 (1983) 1262-1267